City Center Advisors LLC Makes New $276,000 Investment in Astrana Health, Inc. (NASDAQ:ASTH)

City Center Advisors LLC purchased a new position in shares of Astrana Health, Inc. (NASDAQ:ASTH) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 8,898 shares of the company’s stock, valued at approximately $276,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Pilgrim Partners Asia Pte Ltd acquired a new stake in Astrana Health during the fourth quarter worth about $40,000. Quarry LP increased its stake in Astrana Health by 35.5% during the fourth quarter. Quarry LP now owns 1,799 shares of the company’s stock worth $57,000 after acquiring an additional 471 shares during the last quarter. KBC Group NV increased its stake in Astrana Health by 108.4% during the fourth quarter. KBC Group NV now owns 2,530 shares of the company’s stock worth $80,000 after acquiring an additional 1,316 shares during the last quarter. US Bancorp DE increased its stake in Astrana Health by 3,880.0% during the fourth quarter. US Bancorp DE now owns 4,776 shares of the company’s stock worth $151,000 after acquiring an additional 4,656 shares during the last quarter. Finally, PharVision Advisers LLC acquired a new stake in Astrana Health during the fourth quarter worth about $211,000. 52.77% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have commented on ASTH shares. Stifel Nicolaus dropped their price target on Astrana Health from $70.00 to $56.00 and set a “buy” rating for the company in a research note on Thursday, February 20th. Bank of America lowered their target price on Astrana Health from $55.00 to $49.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th. Barclays started coverage on Astrana Health in a research note on Tuesday, April 1st. They issued an “equal weight” rating and a $36.00 target price for the company. Robert W. Baird lowered their target price on Astrana Health from $86.00 to $50.00 and set an “outperform” rating for the company in a research note on Monday, March 3rd. Finally, Truist Financial lowered their target price on Astrana Health from $50.00 to $46.00 and set a “buy” rating for the company in a research note on Tuesday, March 18th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $53.29.

Astrana Health Trading Up 1.9%

Shares of ASTH opened at $25.26 on Friday. The company has a market capitalization of $1.42 billion, a P/E ratio of 19.43, a P/E/G ratio of 1.37 and a beta of 0.85. Astrana Health, Inc. has a one year low of $23.12 and a one year high of $63.20. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91. The stock has a 50-day moving average price of $29.12 and a 200 day moving average price of $32.89.

Astrana Health (NASDAQ:ASTH) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.09). The business had revenue of $620.39 million during the quarter, compared to analysts’ expectations of $628.11 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The company’s revenue for the quarter was up 53.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.31 EPS. Sell-side analysts forecast that Astrana Health, Inc. will post 1.15 EPS for the current fiscal year.

Astrana Health Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.